試す - 無料

Public Goods for Health is a concept which is very much a focus of WHO

BioSpectrum Asia

|

March 2020

From Director General (DG), Indian Council of Medical research (ICMR) and Secretary, Department of Health Research, Dr Soumya Swaminathan went to Geneva in October 2017 to take over as the Deputy Director General (DDG) of Programmes at the World Health Organisation (WHO), to be the first Indian to hold this position. Exactly a year back, in March 2019, she took over as the WHO’s first Chief Scientist, a new position heading a division created as a part of sweeping reforms at WHO to have an explicit focus on science. A year after taking over the new and important position at an international level that is expected to create a foundation for a new department, Dr. Soumya Swaminathan spoke to Milind Kokje, chief editor, BioSpectrum while she was in Chennai, India recently about her new role, its responsibilities and other health related issues. Edited excerpts;

- Milind Kokje

Public Goods for Health is a concept which is very much a focus of WHO

How would you describe your current international stint as a Chief Scientist of World Health Organisation (WHO)? How has been your experience since you took over in March 2019?

The role of the Chief Scientist is a new one and it is very interesting and a challenging position. It is a new position created in WHO. Although WHO is the science-based organization, Dr. Adhanom Tedros, Director General, WHO, wants to ensure that there is an explicit focus on science and hence this new division and a new position to head that division was created.

Our mission is two-fold. First, to ensure that WHO stays ahead of the curve to have sight on what is coming in terms of new scientific and technological developments. Not only because those developments can be leveraged for public health, but also, we need to be prepared to meet some of the new challenges, especially ethical and regulatory challenges which invariably are associated with new technology as there are risks that need to be addressed and minimized. That is one of our major focus.

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size